With today’s medicines, most people with chronic myeloid leukemia (CML) have a normal lifespan and a good quality of life. The key is to get care from CML experts — like the physicians at Fred ...

Treatment for Chronic Myelogenous Leukemia Published August 6, 2008 • Updated on October 4, 2008 at 3:33 pm • Updated on October 4, 2008 at 3:33 pm ...

Treatment for Chronic Myelogenous Leukemia Published August 6, 2008 • Updated on October 4, 2008 at 3:33 pm. BOOKMARKER ...

Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-1061.

If you've been diagnosed with CML, or chronic myelogenous leukemia, you know that your bone marrow is making cells from early versions of certain blood cells. Your treatment will be geared toward ...

Therapy of CML has been remarkably changed by the development and introduction in the clinical setting of the tyrosine kinase inhibitor imatinib mesylate (formerly STI-571). Imatinib was approved ...

To have treatment value, any new TKI should cost $40000-$50000 per quality adjusted life year, which is defined as the quality and duration of life after a novel TKI vs with the existing standard ...

ICLUSIG is a kinase inhibitor primarily targeting BCR-ABL1, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic ...

Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP). The following article features coverage from the American Society of Hematology ...

Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...

Previous experience in the treatment of chronic myeloid leukaemia (CML) has shown that the achievement of clinical, morphological and cytogenetic remission does not indicate eradication of the ...

Ask the Expert: More about Treatment-free CML after TKI —In the second part of this interview, Michael J. Mauro, MD, discusses the possible risks of stopping TKI therapy and what we still need ...